分组1 - Landstar System reported quarterly earnings of $1.24 per share, exceeding the Zacks Consensus Estimate of $1.19 per share, but down from $1.31 per share a year ago, resulting in an earnings surprise of +4.20% [1] - The company posted revenues of $1.17 billion for the quarter ended December 2025, missing the Zacks Consensus Estimate by 1.15%, compared to $1.21 billion in the same quarter last year [2] - Landstar shares have increased approximately 5.6% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $1.15 on revenues of $1.18 billion, and for the current fiscal year, it is $5.55 on revenues of $5.08 billion [7] - The Zacks Industry Rank for Transportation - Truck is currently in the bottom 5% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - Landstar's Zacks Rank is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6]

分组1 - C.H. Robinson Worldwide (CHRW) reported quarterly earnings of $1.23 per share, exceeding the Zacks Consensus Estimate of $1.12 per share, and showing an increase from $1.21 per share a year ago, resulting in an earnings surprise of +9.73% [1] - The company posted revenues of $3.91 billion for the quarter ended December 2025, which was below the Zacks Consensus Estimate by 1.18%, and a decrease from $4.18 billion in the same quarter last year [2] - C.H. Robinson has surpassed consensus EPS estimates for the last four quarters but has not beaten consensus revenue estimates during the same period [2] 分组2 - The stock has gained approximately 12.2% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] - The current consensus EPS estimate for the upcoming quarter is $1.26 on revenues of $4.12 billion, and for the current fiscal year, it is $5.84 on revenues of $17.11 billion [7] - The Transportation - Services industry, to which C.H. Robinson belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - Weyerhaeuser Company (WY) is expected to report fourth-quarter 2025 results on January 29, reflecting ongoing challenges in the housing and wood products market [1] - The company has consistently beaten earnings estimates in three of the last four quarters, with an average surprise of 65.7% [2] Earnings Estimates - The Zacks Consensus Estimate for the upcoming quarter's loss per share has widened to 13 cents from 12 cents, compared to an earnings per share (EPS) of 11 cents in the same quarter last year [3] - The consensus for net sales is projected at $1.58 billion, indicating a 7.2% year-over-year decline [3] Factors Influencing Q4 Results - Revenues are likely pressured by seasonally softer housing and repair-and-remodel activity, impacting demand in the Wood Products segment, which accounted for approximately 71.5% of third-quarter 2025 net sales [4] - Lumber and oriented strand board (OSB) pricing remained near historically low levels, with a 10% sequential decline in lumber output expected due to weaker market conditions [4] - The Timberlands segment's revenue trends are mixed, with domestic log demand softening in the Western region but stable demand in the U.S. South [6] Segment Performance - Wood Products segment net sales are expected to decline 9.7% year-over-year to $1.14 billion, with adjusted EBITDA projected to drop 96.2% to $6.1 million [5] - Timberlands segment net sales are anticipated to grow 2.9% to $511.4 million, while adjusted EBITDA is expected to decline 6.2% to $118.2 million [7] - The Real Estate, Energy and Natural Resources segment's net sales are projected to be $81.8 million, down 4.9% year-over-year, with adjusted EBITDA expected to increase 1.7% to $77.3 million [10] Margin Performance - Overall margin performance in Q4 is expected to remain under pressure, particularly in Wood Products, due to weak lumber and OSB pricing and lower operating rates [11] - Cost offsets, including a decline in log and fiber costs, are expected to cushion earnings volatility [12] Earnings Prediction Model - The model does not predict an earnings beat for Weyerhaeuser this time, with an Earnings ESP of -27.28% and a Zacks Rank of 3 [13]

Core Insights - Invesco Mortgage Capital Inc. (IVR) is set to report its fourth-quarter 2025 results on January 29, 2026, with expectations of year-over-year growth in earnings available for distribution per common share [1][10] Group 1: Earnings Performance - In the last reported quarter, IVR posted earnings available for distribution per common share of 58 cents, with an average negative earnings surprise of 0.61% over the past four quarters [2][6] - The Zacks Consensus Estimate for fourth-quarter earnings remains unchanged at 58 cents, indicating a 9.4% increase from the same quarter last year [6] Group 2: Market Conditions - The mREIT sector experienced favorable conditions in the fourth quarter due to lower volatility in fixed-income markets, which likely tightened mortgage spreads and improved IVR's book value per share [4][10] - The Federal Reserve's two interest rate cuts in the fourth quarter led to a significant drop in mortgage rates, with the 30-year fixed mortgage rate falling below 6%, potentially increasing mortgage demand and refinancing activities [5][10] Group 3: Operational Impacts - The decline in mortgage rates is expected to have resulted in a rise in refinancing and origination volumes, which may have increased the mortgage servicing rights amortization for IVR [5][10]

Core Viewpoint - Eli Lilly (LLY) is positioned to potentially continue its earnings-beat streak in the upcoming report, having a history of exceeding earnings estimates, particularly in the last two quarters with an average surprise of 14.54% [1] Earnings Performance - For the last reported quarter, Eli Lilly achieved earnings of $7.02 per share, surpassing the Zacks Consensus Estimate of $6.02 per share, resulting in a surprise of 16.61% [2] - In the previous quarter, the company was expected to report earnings of $5.61 per share but delivered $6.31 per share, yielding a surprise of 12.48% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Eli Lilly, with a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of an earnings beat [5] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced a positive surprise nearly 70% of the time, suggesting a high probability of exceeding consensus estimates [6] Earnings ESP Metric - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate [7] - Eli Lilly currently has an Earnings ESP of +0.05%, indicating recent bullish sentiment among analysts regarding the company's earnings prospects [8] Upcoming Earnings Report - The next earnings report for Eli Lilly is expected to be released on February 4, 2026, and the combination of a positive Earnings ESP and a Zacks Rank of 3 suggests a potential for another earnings beat [8]

Core Viewpoint - Piper Sandler Companies (PIPR) has a strong history of beating earnings estimates and is well-positioned for future earnings surprises, particularly with an average surprise of 38.65% over the last two quarters [1][5]. Earnings Performance - For the most recent quarter, Piper Sandler reported earnings of $3.82 per share, exceeding the expected $2.96 per share by a surprise of 29.05% [2]. - In the previous quarter, the company reported $2.95 per share against an estimate of $1.99 per share, resulting in a surprise of 48.24% [2]. Earnings Estimates and Predictions - Estimates for Piper Sandler have been trending higher, supported by its history of earnings surprises [5]. - The company currently has an Earnings ESP of +1.06%, indicating a bullish outlook from analysts regarding its earnings prospects [8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat in the upcoming report [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Cemex (CX) - Cemex currently holds a Momentum Style Score of B, indicating a positive momentum outlook [3] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [4] Performance Metrics - Over the past week, Cemex shares increased by 3.36%, while the Zacks Building Products - Concrete and Aggregates industry declined by 0.46% [6] - In a longer timeframe, Cemex shares rose by 10.94% over the past month, outperforming the industry's 2.48% [6] - Over the last quarter, shares of Cemex increased by 28.29%, and over the past year, they gained 120.55%, compared to the S&P 500's increases of 1.81% and 17.32%, respectively [7] Trading Volume - The average 20-day trading volume for Cemex is 5,625,169 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, three earnings estimates for Cemex have been revised upwards, with no downward revisions, raising the consensus estimate from $0.92 to $1.00 [10] - For the next fiscal year, three estimates have also moved upwards without any downward revisions [10] Conclusion - Given the positive momentum indicators and earnings outlook, Cemex is positioned as a strong buy candidate for investors seeking short-term opportunities [12]

Core Viewpoint - The article compares The Cooper Companies (COO) and West Pharmaceutical Services (WST) to determine which stock is more attractive to value investors [1] Group 1: Zacks Rank and Earnings Outlook - Both COO and WST currently have a Zacks Rank of 2 (Buy), indicating a positive earnings outlook due to favorable analyst estimate revisions [3] - The Zacks Rank is a strategy that targets companies with positive earnings estimate revision trends, which is beneficial for investors [2] Group 2: Valuation Metrics - COO has a forward P/E ratio of 17.91, while WST has a forward P/E of 31.34, suggesting COO is more attractively priced [5] - COO's PEG ratio is 2.30, compared to WST's PEG ratio of 3.31, indicating that COO may offer better value relative to its expected earnings growth [5] - COO has a P/B ratio of 1.95, while WST has a P/B of 5.67, further supporting the notion that COO is undervalued compared to WST [6] Group 3: Value Grades - Based on various valuation metrics, COO holds a Value grade of B, while WST has a Value grade of C, indicating that COO is the superior value option at this time [6]

Core Insights - Amgen (AMGN) is set to report its fourth-quarter and full-year 2025 results on February 3, with earnings expected to be $4.74 per share and sales at $9.46 billion, reflecting a 12.8% earnings surprise in the last reported quarter [1][10]. Group 1: Sales Performance - Product sales are anticipated to be driven by strong volume growth from drugs like Evenity, Repatha, and Blincyto, although prices are expected to decline due to increased rebates [2]. - The Zacks Consensus Estimate for sales of Evenity, Repatha, and Blincyto is $559 million, $798 million, and $434 million, respectively [3]. - Newer drugs such as Imdelltra, Tavneos, and Tezspire are expected to contribute to top-line growth, alongside sales from rare disease drugs like Uplizna, estimated at $183 million [4]. Group 2: Patent Expirations and Competitive Pressures - Patents for key drugs Prolia and Xgeva expired in February 2025 in the U.S., leading to expected sales erosion due to the launch of biosimilars, with estimates of $980 million for Prolia and $444 million for Xgeva [5]. - Competitive pressures have negatively impacted volume growth for Kyprolis, with an estimated sales figure of $365 million, while Enbrel sales are likely to decline due to price reductions [6]. Group 3: Biosimilars and R&D Costs - Amgen's biosimilars, including Wezlana and Pavblu, are expected to contribute to sales growth, although Wezlana is not expected to generate U.S. sales in the fourth quarter [7]. - Lower revenues from oncology biosimilars and legacy products are anticipated, alongside higher R&D costs that may negatively impact operating margins [8][9]. Group 4: Earnings Expectations - Amgen's Earnings ESP is -0.40%, indicating a lower likelihood of an earnings beat, with the most accurate estimate at $4.72 per share compared to the consensus of $4.74 [13][14].

Core Viewpoint - A. O. Smith Corporation (AOS) is set to release its fourth-quarter 2025 results on January 29, with expectations of a slight revenue increase but a decline in adjusted earnings per share [1][2][10]. Financial Performance Expectations - The Zacks Consensus Estimate for AOS's revenues is $923.7 million, reflecting a 1.2% increase from the prior-year quarter [2]. - The consensus estimate for adjusted earnings is 84 cents per share, indicating a 1.2% decline from the year-ago quarter [2]. Segment Performance Insights - Strong demand for commercial water heaters and boilers is anticipated to boost the North America segment's revenues by 1.8% year over year to $702.4 million [3]. - Recent acquisitions, including the Pureit business from Unilever and Impact Water Products, are expected to positively impact AOS's top line and enhance its water treatment offerings [4][5]. Challenges and Risks - The ongoing challenges in the Chinese real estate market are likely to negatively affect the Rest of the World segment, with expected revenues decreasing by 3% year over year to $229.6 million [6]. - AOS is facing rising costs, with SG&A expenses projected to increase by 11.1% year over year to $202.2 million, which may pressure its bottom line [7]. - Foreign currency headwinds are also expected to impact profitability due to the company's significant international operations [7]. Earnings Prediction Insights - The current Earnings ESP for AOS is 0.00%, indicating no expected earnings beat, as both the Most Accurate Estimate and the Zacks Consensus Estimate are at 84 cents per share [9]. - AOS holds a Zacks Rank of 3, suggesting a neutral outlook for the stock [11].